

Publisher: Bentham Science Publishers
E-ISSN: 1873-5592|11|12|1495-1503
ISSN: 1389-4501
Source: Current Drug Targets, Vol.11, Iss.12, 2010-12, pp. : 1495-1503
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
As an enzyme, heme oxygenase (HO) can provide substantial cellular protection. By eliminating free heme and generating iron, biliverdin, as well as carbon monoxide, HO exerts anti-inflammatory, anti-proliferative, antioxidative, and vasodilatory effects. The inducible form of HO, heme oxygenase-1 (HO-1) can be upregulated by harmful stimuli in most human cell types. In such a way, cells utilize HO-1 as a mechanism of self-protection. Many studies have shown that upregulation of HO-1 prior to injurious stimuli conferred protection to cells and organs against subsequent injury. Therefore, manipulation of HO-1 gene expression might represent a valuable strategy for the prevention of organ dysfunction. In recent studies, intravenous and inhaled anesthetics (e.g., ketamine, propofol, opioids, isoflurane, sevoflurane, desflurane, etc.) not only upregulate HO-1 to varying extents, but account for organ protection via the HO pathway. The major advantage of anesthetics over other HO-inducing agents is related to their clinically proven safety. Another important issue is that patients receiving anesthetics in anesthesia or intensive care medicine are often suffering from pathological conditions involving pro-oxidative or pro-inflammatory states. Therefore, it would be interesting to know whether the impact of anesthetics on HO-1 regulation might influence outcome of these patients. This overview summarizes the effects of different anesthetics on HO-1 regulation and function in disease models.
Related content


Role of Heme Oxygenase-1 in Cardiovascular Function
Current Pharmaceutical Design, Vol. 9, Iss. 30, 2003-11 ,pp. :




Role of Heme Oxygenase-1 in Vascular Disease
Current Pharmaceutical Design, Vol. 14, Iss. 5, 2008-02 ,pp. :


Current Pharmaceutical Design, Vol. 14, Iss. 5, 2008-02 ,pp. :